LEBANON, N.H.--(BUSINESS WIRE)--Avitide, Inc., a biotech company dedicated to the rapid discovery and development of on-demand affinity purification solutions for the biopharmaceutical industry, today announced the closing of its Series C financing. NeoMed Management led the financing, with participation from existing investors Polaris Partners, OrbiMed Advisors, SV Life Sciences and Borealis Ventures. Claudio Nessi (NeoMed) joined Avitide’s Board of Directors. The proceeds will accelerate commercialization of Avitide’s on-demand affinity purification platform, with a focus on biopharmaceutical drug products that include an array of molecules such as proteins, enzymes, antibody-based therapeutics, recombinant vaccines, gene therapies and biosimilars. The financing is expected to take the company to profitability within the next two years.
Help employers find you! Check out all the jobs and post your resume.
